Top 10 Best-selling Cancer Drugs in 2011
By Tracy StatonOncology drugs are hot. Scratch beneath the surface of most major drugmakers, and you'll find a host of them in various stages of development, as the upcoming American Society of Clinical Oncology meeting will attest.
The usual reasons for growing drug demand apply: Rising healthcare spending in countries such as China; an expanding middle class better able to access healthcare in India and other emerging markets; and aging populations in big drug markets like the U.S. and Japan.
TOP HEADLINES
SPECIAL REPORT
U.K. report says NICE drags its feet on drug approvals
British media are reporting on a study suggesting that U.K. patients twiddle their thumbs for up to 9 years as the National Institute for Health and Clinical Excellence deliberates over new products.
New discount persuades NICE to bless J&J's Zytiga
Britain's cost-effectiveness watchdog reversed its decision against the Johnson & Johnson prostate cancer pill, thanks to the company's new discount offer.
ASCO data to shine new light on Pfizer, Roche, J&J drugs
Cancer drug aficionados, rejoice. A slew of new studies goes public later today, as drugmakers gear up for next month's American Society of Clinical Oncology meeting.
Pennsylvania still trying get a slice of J&J Risperdal payouts
PA alleges that J&J oversold the drug's benefits while underselling the risks.
NIH taps Genentech drug for pioneering Alzheimer's study
Researchers will test crenezumab in Colombians with a particular genetic mutation, aiming to see if the drug can stop Alzheimer's before it starts.
Ex-BMS exec finishes book, and sentence, in conviction
A former Bristol-Myers Squibb executive has completed his sentence with a book on the Plavix scandal.
From Our Sister Sites
Knode has sprung to life with web-based software to enable life sciences stakeholders to hunt for top experts.
The deal comes amid rapid business expansion at Decision Resources, which provides web-based research tools, predictive analytics and other services to drugmakers and other healthcare stakeholders.
POPULAR COMMENT THREADS